Skip to main content
S&P 5007,615.85+0.40%DOW52,101.39+0.02%NASDAQ26,187.71+0.79%BTC$75,686.00-0.38%ETH$2,391.20-0.61%GOLD$4,390.20+1.32%OIL$102.99-2.68%
Smart Investors Daily
MediWound Ltd. logo

NASDAQ · MDWD

MediWound Ltd.

Healthcare · Biotechnology

$13.47

Up+$0.06 (+0.45%)

Updated Sep 16, 2026, 3:07 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
209.54M
P/E ratio
-7.4
Dividend yield
0.00%
52-week range
$12.52 – $20.03
Volume
80.53K
Avg. volume
79.29K

Price performance

MDWD price history

1M range · 20 trading sessions · Daily adjusted prices

MDWD closed at $13.47 after 20 trading sessions, down 1.25% for the selected period.

Last close
$13.47
Period change
-1.25%
Period low
$12.61
Period high
$13.88
Daily close
View OHLC price history
MDWD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$13.74$13.74$13.19$13.4780.53K
Sep 14, 2026$13.17$14.00$13.17$13.88167.85K
Sep 11, 2026$13.81$13.81$12.95$13.1178.33K
Sep 10, 2026$13.74$13.82$13.385$13.71149.83K
Sep 9, 2026$13.44$14.07$13.21$13.84216K
Sep 8, 2026$13.20$13.67$13.06$13.44195.09K
Sep 4, 2026$13.13$13.41$13.03$13.2986.16K
Sep 3, 2026$13.10$13.33$12.795$13.2191.16K
Sep 2, 2026$12.71$13.13$12.7001$13.06104.15K
Sep 1, 2026$12.72$12.99$12.585$12.62108.5K
Aug 31, 2026$12.67$12.95$12.55$12.61167.03K
Aug 28, 2026$13.18$13.18$12.52$12.66165.53K
Aug 27, 2026$12.72$13.25$12.72$13.24196.22K
Aug 26, 2026$13.00$13.085$12.61$12.70209.56K
Aug 25, 2026$13.07$13.13$12.85$12.9780.36K
Aug 24, 2026$13.19$13.27$12.86$13.00101.56K
Aug 21, 2026$13.15$13.32$13.065$13.2179.83K
Aug 20, 2026$13.60$13.60$13.06$13.11581.39K
Aug 19, 2026$13.75$13.78$13.53$13.5953.61K
Aug 18, 2026$13.44$13.80$13.44$13.6456.42K

Latest MDWD news

The latest Smart Investors Daily articles mentioning MDWD.

Stock researchCompany · Overview

MDWD research

Overview

Company profile and research snapshot.

Company profile

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$36.00
Implied upside
—
Analysts
—
MDWD recent ratings
DateFirmRatingTarget
Aug 14, 2026OppenheimerOutperform—
May 28, 2026OppenheimerOutperform—
May 28, 2026HC Wainwright & Co.Buy—
Nov 21, 2025HC Wainwright & Co.Buy—
May 22, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. The f

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By